MDCO News and Press, The Medicines Company From 01/21/19

Merger Monday is alive and well in the healthcare sector with two big acquisitions thus far in 2019 with Bristol-Myers agreeing to buy Celgene Corp. in a deal valued at $74 billion and Eli Lilly & Company agreeing to acquire Loxo Oncology Inc. for roughly $8 billion. Only time will tel...

2019 is a momentous year for inclisiran, a first in class therapy with the potential to deliver potent, durable and consistent lowering of LDL-C levels via twice-a-year dosing. With full commercial rights in all geographies, The Medicines Company is well placed to harness the intrinsic...

Happy Holidays! If a Santa Claus rally was supposed to materialize this year, it has yet to happen and the S&P 500 once again declined for the third week in a row. The pace of selling accelerated with a 7% drop last week. There could be various reasons for this market correction ranging ...

There are two criticisms you’ll never read about Alnylam ( ALNY ) – that management is insufficiently promotional of the company, and that it doesn’t have enough pipeline candidates/ideas. Always a company with many irons in the fire, Alnylam hosted an R&D day Thursd...

ACIW , AZN , BAM , CAH , CBB , CBM , CEVA , CHH , CNNE , CNP , COMM , COT , CRCM , CROX , DESP , DHI , DISCA , DNR , EBIX , ENDP , FLY , GCI , GPRE , GTT , HAIN , HII , HIMX , HL , HMHC , HRI , IMOS , JCI , KOP , LAMR , LAUR , LGND , LNG , LOXO , MDCO ...

NEW YORK, Nov. 05, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SkyWest, Inc. (NASDAQ:SKYW), Blueprint Medicines Corporation (NASDAQ:BPMC...

The Medicines Company (NASDAQ:MDCO) will host a conference call and audio webcast on Thursday, November 8, 2018, at 8:30 a.m., EST, to discuss its third-quarter 2018 financial results and operational developments. The conference call may be accessed by telephone as follows: U.S./Cana...

This article is part of a series that provides an ongoing analysis of the changes made to David Einhorn's Greenlight Capital 13F portfolio on a quarterly basis. It is based on Einhorn's regulatory 13F Form filed on 08/14/2018. Please visit our Tracking David Einhorn's Greenlight Capital Hol...